- Galectin Therapeutics
Galectin Therapeutics develops novel therapies to improve the lives of patients with chronic liver disease and cancer Galectin’s lead drug, belapectin (GR‑MD‑02), is a carbohydrate-based drug that inhibits the galectin‑3 protein, involved in many inflammatory, fibrotic, and malignant diseases
- Galectin Therapeutics Inc. (GALT) Stock Price, News, Quote . . .
Find the latest Galectin Therapeutics Inc (GALT) stock quote, history, news and other vital information to help you with your stock trading and investing
- GALT: Galectin Therapeutics Inc Latest Stock Price, Analysis . . .
Get real-time Galectin Therapeutics Inc (GALT) stock price, news, financials, community insights, and trading ideas Join 10 million+ investors and traders tracking markets in real-time on Stocktwits
- Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200 . . .
Galectin Therapeutics Company Profile (Get Free Report) Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases
- Driving innovation in Galectin-3 targeted therapeutics to
Galytx is a biotech company that develops galectin-3 targeted novel therapeutics Galectin-3 is a molecular target of exceptional clinical relevance in cancer, fibrosis and inflammation Over expression of galectin-3 is an important driver of morbidity and mortality associated with these diseases
- Galecto, Inc. – The leading developer of galectin and ENL . . .
Galecto, Inc develops small molecules for the treatment of cancer and severe liver diseases The company is built on nearly 15 years of research centering on the role of galectin-3 and the use of modulators of these proteins to treat cancer and severe liver diseases
- Galectin Therapeutics Presents NAVIGATE Trial Results at EASL . . .
Galectin Therapeutics announced positive results from its NAVIGATE trial of belapectin, a galectin-3 inhibitor, for patients with MASH cirrhosis and portal hypertension
|